Antidiabetics Market 2020 By Revenue, Top Trend & Regional Growth Forecast

Antidiabetics Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

The global antidiabetics market is slated to foresee tremendous business expansion through the forthcoming years due to the increasing prevalence of diabetes across the world. In fact, as per the WHO (World Health Organization), about 422 million people across the world are diagnosed with diabetes with more than 1.6 million global deaths directly caused by diabetes-related complications every year. To offer better treatment options and effectively decrease this high mortality rate, antidiabetics demand is estimated to increase heavily over the coming years.

Subsequently, an upsurge in drug development efforts and the increasing adoption of oral antidiabetics is likely to complement the market size further. Antidiabetic drugs are medicines made to control and stabilize blood glucose levels in people suffering from diabetes.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/504

The growing trend of integrating antidiabetics with technologically advanced diabetes treatment devices should majorly augment the overall market share. Taking May 2019 for instance, Roche Diabetes Care launched its novel Integrated Diabetes Management Solution (IDMS) through the launch of the “mySugr” app as well as the “Accu-Chek Instant” blood glucose monitoring system. These solutions together form a new generation of technologically advanced blood glucose monitoring system.

With regards to product, the market is categorized into drug class and insulin. The drug class is further characterized by alpha-glucosidase inhibitors, biguanides, sulphonylureas, GLP-I, DPP-IV, meglitinides, SGLT-II, and thiazolidinedione. Of these, in 2019, the DPP-IV segment held a share of more than $8 billion in terms of revenue. The segment is likely to exhibit a massive growth through the forecast timespan owing to its benefits such as decreasing postprandial and fasting blood glucose levels while not causing an increase in weight. Due to this, the product is used to treat type-2 diabetic patients.

In terms of the patient population, the industry is classified into a pediatric, adult, and geriatric. Of these, the pediatric segment is projected to expand at a healthy CAGR of more than 11.5% through the forecast timespan. This growth is attributed to the mounting instances of diabetes cases among children due to the increasing consumption diet that are more carbohydrate-rich.

On the regional front, the Europe antidiabetic industry is estimated to grow at a CAGR of more than 10.7% over the analysis timeframe. the growing demand for novel drugs, mounting drug development, as well as increasing prevalence of oral antidiabetics is slated to drive this growth in the region.

Meanwhile, in an effort to cater to the rising patient population, key companies in the market are aiming at innovating and discovering new drug formulations that can effectively treat or help patients control this ailment. Taking September 2019 for instance, the U.S. FDA approved Rybelsus, a new antidiabetic. Rybelsus is manufactured by Novo Nordisk in order to treat type 2 diabetes among adults.

The competitive landscape of the global antidiabetics market is inclusive of players such as Oramed Pharmaceuticals Inc., Novo Nordisk, Novartis AG, Merck & Co. Inc., Johnson & Johnson, Halozyme Therapeutics, Eli Lilly, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Corporation, and AstraZeneca among others. 

Browse full table of contents (TOC) of this report @ https://www.decresearch.com/toc/detail/antidiabetics-market

Partial Chapter of the Table of Content 

Chapter 4. Antidiabetics Market, By Product

4.1. Key segment trends

4.2. Insulin

4.2.1.  Market size, by region, 2015 - 2026 (USD Million)

4.2.2.  Rapid acting analog

4.2.2.1.  Market size, by region, 2015-2026 (USD Million)

4.2.3.  Long acting analog

4.2.3.1.  Market size, by region, 2015-2026 (USD Million)

4.2.4.  Premixed insulin

4.2.4.1.  Market size, by region, 2015-2026 (USD Million)

4.2.5.  Short acting analog

4.2.5.1.  Market size, by region, 2015-2026 (USD Million)

4.2.6.  Intermediate acting analog

4.2.6.1.  Market size, by region, 2015-2026 (USD Million)

4.3. Drug class

4.3.1.  Market size, by region, 2015 - 2026 (USD Million)

4.3.2.  Alpha glucosidase inhibitors

4.3.2.1.  Market size, by region, 2015-2026 (USD Million)

4.3.3.  Biguanides

4.3.3.1.  Market size, by region, 2015-2026 (USD Million)

4.3.4.  Sulphonylureas

4.3.4.1.  Market size, by region, 2015-2026 (USD Million)

4.3.5.  GLP-1 (Glucagon like peptide) agonists

4.3.5.1.  Market size, by region, 2015-2026 (USD Million)

4.3.6.  DPP-IV (Dipeptidyl Peptidase) inhibitors

4.3.6.1.  Market size, by region, 2015-2026 (USD Million)

4.3.7.  Meglitinides

4.3.7.1.  Market size, by region, 2015-2026 (USD Million)

4.3.8.  SGLT-II (Sodium Glucose Transport Proteins) inhibitors

4.3.8.1.  Market size, by region, 2015-2026 (USD Million)

4.3.9.  Thiazolidinedione

4.3.9.1.  Market size, by region, 2015-2026 (USD Million)

Chapter 5. Antidiabetics Market, By Patient Population

5.1. Key segment trends

5.2. Pediatric

5.2.1.  Market size, by region, 2015 - 2026 (USD Million)

5.3. Adult

5.3.1.  Market size, by region, 2015 - 2026 (USD Million)

5.4. Geriatric

5.4.1.  Market size, by region, 2015 - 2026 (USD Million)